Supernus Acquires Sage Therapeutics for $795M to Expand Neuropsychiatry Pipeline

Published on Spencer Knight via LinkedIn

Supernus Pharmaceuticals is acquiring Sage Therapeutics in a $795 million all-cash deal. Shareholders will receive $12.00 per share, including $8.50 upfront and up to $3.50 in contingent value rights based on future milestones.

The deal adds ZURZUVAE (zuranolone), Sage’s FDA-approved therapy for postpartum depression, to Supernus’ neuropsychiatry portfolio. With projected cost synergies of $200 million per year, the acquisition is expected to become earnings-accretive by 2026.

Spencer Knight calls this a major step for Supernus in strengthening its footprint in neuroscience, especially in depression and mood disorders.

Read the full post on LinkedIn:

👉 Spencer Knight: Supernus to acquire Sage Therapeutics for $795 Million

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.